Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433725 | 0.83 | F10 (0.57) | F10KLKB1 | |
| SCHEMBL2435293 | 0.77 | F10 (0.51) | F10KLKB1 | |
| SCHEMBL2433904 | 0.67 | F10 (0.52) | F10NPC1RAB9A | |
| SCHEMBL2495470 | 0.67 | F10 (0.40) | F10KLKB1KCNH2 | |
| SCHEMBL2433261 | 0.67 | F10 (0.53) | F10KLKB1KCNH2 | |
| SCHEMBL2431759 | 0.66 | F10 (0.53) | F10KLKB1KCNH2 | |
| SCHEMBL2433883 | 0.66 | F10 (0.68) | F10KLKB1KCNH2 | |
| SCHEMBL2436071 | 0.65 | L3MBTL1 (0.50) | RAB9AKDM4E | |
| SCHEMBL2436152 | 0.65 | F10 (0.68) | F10KLKB1KCNH2 | |
| SCHEMBL2433664 | 0.65 | F10 (0.78) | F10KLKB1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542529-B1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | LLC PHARMADIALL (RU) | 2019-09-04 | — | — | EP | disclosed |
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PLAUR, PLAU, UTS2R | F10 9/4885KLKB1 144/4885NPC1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.